PRESS RELEASE November 25 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the composition of the Nomination Committee for the Annual General Meeting 2022 . Pursuant to the instruction and charter for the Nomination Committee adopted

PRESS RELEASE November 18 , 202 1 Three Months Ended September 30, 2021 (2020) Revenue was SEK 2.3 M (2.2 M) Operating loss was SEK -88.2 M (-37.3 M) Net loss was SEK -93.7 M (-48.3 M) Basic loss per share was SEK -1.50 (-1.14) Diluted loss per share was SEK -1.50 (-1.14) Nine Months Ended

PRESS RELEASE November 1 7 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with hypothalamic obesity (HO). Tesomet is an investigational fixed-dose combination